Tri-Institutional Therapeutics Discovery Institute, Inc.

Tri-Institutional Therapeutics Discovery Institute, Inc. Tri-Institutional Therapeutics Discovery Institute, Inc. is a collaboration of WCMC, The Rockefeller University and Memorial Sloan Kettering Cancer Center.

Memorial Sloan-Kettering Cancer Center, The Rockefeller University and Weill Cornell Medical College have formed the pioneering Tri-Institutional Therapeutics Discovery Institute, Inc. (Tri-I TDI) and have partnered with Takeda Pharmaceutical Company, Ltd. (TSE:4502). This new, groundbreaking institute, designed to expedite early-stage drug discovery into innovative treatments and therapies for pa

tients, was founded thanks to a generous $15 million gift by Lewis and Ali Sanders and a $5 million gift from Howard and Abby Milstein. The Tri-Institutional Therapeutics Discovery Institute represents a novel partnership of academic institutions working together to more effectively develop therapeutics that arise from discoveries made in basic science labs. Its focus is on the early stages of developing compounds that make possible all-important “proof of concept” studies – those that increase the likelihood that targeting a specific biologic pathway can favorably alter the course of a disease. Read more:
https://www.tritdi.org/news/news20131001

Address

New York, NY

Telephone

646-962-6127

Website

Alerts

Be the first to know and let us send you an email when Tri-Institutional Therapeutics Discovery Institute, Inc. posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share

Category